Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig)
nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a
3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches